|
Followers
|
287
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
25749
|
|
Created
|
02/15/11
|
Type
|
Free
|
| Moderators | |||
Halberd Corp. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.
HALB holds the exclusive rights to 3 granted U.S. Patents, no. 9,216,386 no. 8,758,287 and no. 11,186,629
See YouTube video, https://youtu.be/BGdZqHH6oew, concerning Dr. Felder’s discussion of the scientific basis underlying Premier’s extracorporeal treatment process for fighting cancer and other diseases.
In plain English: Halberd Corporation is a biotechnology company and with its partners (Dr. Qiang Shawn Chen and his team at Arizona State University; Dr. William Sturrus and his team at Youngstown State University) is developing an extra-corporeal (out of the body) treatment against PTSD, CTE, Alzheimer's Disease and other virusses and diseases. With the use of antibodies the disease antigens is targeted. Using radiofrequency / laser technology the "antibody-metallic moiety-antigens complex" is destroyed/eradicated. All based on 3 granted patents and 22 provisional/non-provisional (some PCT) patent applications.
CEO William Hartman: "The principal competitive Alzheimer's drug treatment available today eliminates 5-15% of Beta Amyloid after one month of treatment costing over $50,000 per year. Halberd's extracorporeal process eradicates 100% within just 10 minutes."
JACKSON CENTER, PA / ACCESSWIRE / March 14, 2023 / Halberd Corporation (OTC PINK:HALB) is scheduled to meet with Center of Disease Control (CDC) representatives to discuss Halberd's incredible success in eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and Candida auris samples previously provided by the CDC. MEETING WITH CDC ON MARCH 29 2023!!!
JACKSON CENTER, PA / ACCESSWIRE / January 31, 2023 / Halberd Corporation (OTC PINK:HALB) confirmed that animal testing at Mississippi State University (MSU) will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury.
